Clinical Trial Results
FONT-SIZE Plus   Neg

Mylan's Combination Drug Gets Tentative FDA Approval Under PEPFAR

Mylan Inc. (MYL: Quote) said its subsidiary Mylan Laboratories Limited received tentative approval from FDA for its New Drug Application for Abacavir Sulfate and Lamivudine Tablets, 60 mg/30 mg. This fixed-dose combination is intended to treating children with HIV/AIDS. The approval is under the President's Emergency Plan for AIDS Relief or PEPFAR.

The combination is based on the adult-strength, brand version of the product Epzicom, by Viiv Healthcare.

Mylan also has received approval for this pediatric FDC therapy from the World Health Organization under their Prequalification of Medicines Programme.

Click here to receive FREE breaking news email alerts for Mylan Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback:

comments powered by Disqus
FREE Newsletters, Analysis & Alerts


Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.